---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-243558"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:15:00.757875+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports Phase 2 darovasertib data: median OS 21.1 mo in 1L mUM; 57% eye preservation

## Summary
- Darovasertib + crizotinib in 1L mUM: median OS 21.1 mo (historical ~12 mo), median PFS 7.0 mo, ORR 34%, DCR 90%.
- Neoadjuvant darovasertib in primary UM: 83% (78/94) of patients achieved tumor shrinkage; 54% >=20% shrinkage.
- Among patients recommended for enucleation, 57.1% (24/42) achieved eye preservation; in those with >=20% shrinkage, rate jumped to 95%.
- Predicted radiation reduction: 70% of Cohort 2 patients saw any reduction in predicted dose to critical eye structures; 64.9% had reduced 3-year vision loss risk.
- FDA Breakthrough Therapy Designation for neoadjuvant darovasertib; registration-enabling Phase 2/3 OptimUM-02 targeting median PFS data by year-end 2025 to Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-243558
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525243558/0001193125-25-243558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525243558/d42028d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-243558
- JSON: https://secwatch.observer/filing/0001193125-25-243558.json
- Plain text: https://secwatch.observer/filing/0001193125-25-243558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.